ES2499391T3 - Método para la producción de anticuerpos - Google Patents

Método para la producción de anticuerpos Download PDF

Info

Publication number
ES2499391T3
ES2499391T3 ES08838661.0T ES08838661T ES2499391T3 ES 2499391 T3 ES2499391 T3 ES 2499391T3 ES 08838661 T ES08838661 T ES 08838661T ES 2499391 T3 ES2499391 T3 ES 2499391T3
Authority
ES
Spain
Prior art keywords
antibody
fragment
dna encoding
copies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08838661.0T
Other languages
English (en)
Other versions
ES2499391T5 (es
Inventor
Yoshiki Yamada
Tatsuya Kiyasu
Kazuyuki Tabata
Akihiro Kuzumaki
Mai Yamashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2499391(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2499391T3 publication Critical patent/ES2499391T3/es
Publication of ES2499391T5 publication Critical patent/ES2499391T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método de producción de un anticuerpo IgG1 o un fragmento del mismo, que comprende permitir a una célula producir el anticuerpo o el fragmento, en el que la célula contiene un número mayor de copias de ADN exógeno que codifica la cadena ligera del anticuerpo o un fragmento de la misma que el número de copias de ADN exógeno que codifica la cadena pesada del anticuerpo o un fragmento de la misma, y es una célula en la que se ha introducido un vector que comprende una copia de ADN que codifica la cadena pesada del anticuerpo o un fragmento de la misma y dos o más copias de ADN que codifica la cadena ligera del anticuerpo o un fragmento de la misma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES08838661T 2007-10-15 2008-10-14 Método para la producción de anticuerpos Active ES2499391T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007267384 2007-10-15
JP2007267384 2007-10-15
JP2008103308 2008-04-11
JP2008103308 2008-04-11
PCT/JP2008/068588 WO2009051108A1 (ja) 2007-10-15 2008-10-14 抗体の製造方法

Publications (2)

Publication Number Publication Date
ES2499391T3 true ES2499391T3 (es) 2014-09-29
ES2499391T5 ES2499391T5 (es) 2021-12-22

Family

ID=40567372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08838661T Active ES2499391T5 (es) 2007-10-15 2008-10-14 Método para la producción de anticuerpos

Country Status (17)

Country Link
US (3) US9683027B2 (es)
EP (1) EP2202307B2 (es)
JP (4) JP4976502B2 (es)
KR (1) KR101558009B1 (es)
CN (3) CN101802192A (es)
AU (1) AU2008312937B2 (es)
BR (1) BRPI0818674B1 (es)
CA (1) CA2701338C (es)
DK (1) DK2202307T4 (es)
ES (1) ES2499391T5 (es)
IL (2) IL205051A (es)
MX (1) MX2010004007A (es)
PL (1) PL2202307T5 (es)
SG (1) SG185302A1 (es)
SI (1) SI2202307T2 (es)
TW (1) TWI463010B (es)
WO (1) WO2009051108A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185302A1 (en) 2007-10-15 2012-11-29 Chugai Pharmaceutical Co Ltd Method for production of antibody
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
CN103282509A (zh) * 2010-12-28 2013-09-04 中外制药株式会社 动物细胞的培养方法
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
WO2025134341A1 (ja) * 2023-12-22 2025-06-26 中外製薬株式会社 抗体の製造方法
WO2025141786A1 (ja) * 2023-12-27 2025-07-03 中外製薬株式会社 抗体の製造方法
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0548267A4 (en) † 1990-09-04 1994-11-23 Salk Inst Biotech Ind Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US5531053A (en) 1994-06-14 1996-07-02 Hamm; Hans Spring fastener for holding insulation against an inner surface of cavity walling
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998047343A2 (en) * 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2002307037B2 (en) † 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US6605176B2 (en) 2001-07-13 2003-08-12 Taiwan Semiconductor Manufacturing Co., Ltd. Aperture for linear control of vacuum chamber pressure
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
MXPA04004634A (es) * 2001-11-16 2004-08-12 Idec Pharma Corp Expresion policistronica de anticuerpos.
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
GB0425534D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
MX2008000985A (es) * 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
SG185302A1 (en) * 2007-10-15 2012-11-29 Chugai Pharmaceutical Co Ltd Method for production of antibody

Also Published As

Publication number Publication date
IL240122A0 (en) 2015-09-24
JPWO2009051108A1 (ja) 2011-03-03
BRPI0818674B1 (pt) 2023-01-17
AU2008312937A1 (en) 2009-04-23
JP2012143246A (ja) 2012-08-02
IL240122B (en) 2019-02-28
PL2202307T3 (pl) 2015-02-27
WO2009051108A1 (ja) 2009-04-23
SI2202307T2 (sl) 2021-11-30
CA2701338C (en) 2018-09-18
DK2202307T4 (da) 2021-10-04
US20100291627A1 (en) 2010-11-18
EP2202307B2 (en) 2021-07-14
BRPI0818674A2 (pt) 2014-10-14
CN106244651A (zh) 2016-12-21
ES2499391T5 (es) 2021-12-22
US12145978B2 (en) 2024-11-19
JP2015198663A (ja) 2015-11-12
SI2202307T1 (sl) 2014-11-28
KR20100074184A (ko) 2010-07-01
CN103540632A (zh) 2014-01-29
TW200934867A (en) 2009-08-16
CA2701338A1 (en) 2009-04-23
JP2017079794A (ja) 2017-05-18
PL2202307T5 (pl) 2021-10-04
EP2202307A1 (en) 2010-06-30
US20170275351A1 (en) 2017-09-28
MX2010004007A (es) 2010-06-15
US9683027B2 (en) 2017-06-20
DK2202307T3 (da) 2014-09-15
CN101802192A (zh) 2010-08-11
US11136375B2 (en) 2021-10-05
US20210300996A1 (en) 2021-09-30
EP2202307B1 (en) 2014-08-20
JP6092304B2 (ja) 2017-03-08
JP6506786B2 (ja) 2019-04-24
JP5788830B2 (ja) 2015-10-07
IL205051A (en) 2015-09-24
JP4976502B2 (ja) 2012-07-18
IL205051A0 (en) 2010-11-30
EP2202307A4 (en) 2012-01-25
TWI463010B (zh) 2014-12-01
AU2008312937B2 (en) 2015-01-22
SG185302A1 (en) 2012-11-29
KR101558009B1 (ko) 2015-10-19

Similar Documents

Publication Publication Date Title
ES2499391T3 (es) Método para la producción de anticuerpos
ES2657060T3 (es) Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas
ES2656427T3 (es) Marcos de inmunoglobulina que demuestran estabilidad mejorada en el ambiente intracelular y métodos para su identificación
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CL2021001506A1 (es) Anticuerpos que se unen a cd3
CY1119046T1 (el) Μεσα κυτταροκαλλιεργειας χωρις ολιγοπεπτιδια
BR112022007283A2 (pt) Sistemas e métodos para microscopia de iluminação estruturada
CO2020012583A2 (es) Métodos para tratar las enfermedades asociadas al vph
ES2535732T3 (es) Escherichia coli productora de L-treonina y proceso para producir L-treonina usando la misma
CU20150156A7 (es) Un método para convertir una materia prima de biomasa en un producto de un ácido amino-alfa omega- dicarboxílico
ES2544974T3 (es) Base, productos que contienen la misma, métodos de preparación y usos de los mismos
CY1118410T1 (el) Θεραπευτικος παραγοντας εναντι της πνευμονικης ινωσης
NO20091439L (no) Forbedring ved celledyrkning
CO2022017249A2 (es) Anticuerpos que se unen a cd3
AR091228A1 (es) Metodo para producir un organismo mejorado vegetal infectado establemente con un endofito
MX2014013838A (es) Codificacion y decodificacion basadas en la mezcla de secuencias de muestras a traves del tiempo.
SV2006002131A (es) Uso de un anticuerpo para el tratamiento de lupus
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
CL2012001640A1 (es) Metodo y sistema para mejorar una imagen referencias cruzadas a solicitudes relacionadas.
BR112021022865A2 (pt) Matriz e método para detectar informações espaciais de ácidos nucleicos
JP2013542501A5 (es)
CY1124624T1 (el) Μητρες οι οποιες περιεχουν εναν τροποποιημενο πολυσακχαριτη
AR085824A1 (es) Anticuerpo anti-receptor il-3 humano
ES2508165T3 (es) Lactoferrina y sustancia blanca